Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,694
  • Shares Outstanding, K 16,683
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,740 K
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.27
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.80 +111.25%
on 01/08/20
2.22 -23.87%
on 01/13/20
+0.85 (+101.33%)
since 12/20/19
3-Month
0.69 +144.86%
on 11/14/19
2.22 -23.87%
on 01/13/20
+0.83 (+96.06%)
since 10/22/19
52-Week
0.69 +144.86%
on 11/14/19
3.25 -48.00%
on 03/18/19
+0.87 (+106.10%)
since 01/22/19

Most Recent Stories

More News
Dare Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene(R) Licensing Agreement and General Corporate Update

Dare Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, January 22, 2020,...

DARE : 1.72 (+3.61%)
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022

Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity....

CNSP : 4.45 (-0.67%)
ADAP : 4.46 (+7.73%)
DARE : 1.72 (+3.61%)
VRNA : 6.40 (-0.31%)
PFE : 40.09 (-0.62%)
AXSM : 88.52 (-0.24%)
Bayer and Dare Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene (R), an Investigational Hormone-Free, Monthly Contraceptive

Bayer, a leader in women's health, and Dare Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health, announced...

DARE : 1.72 (+3.61%)
Dare Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for...

DARE : 1.72 (+3.61%)
Dare Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the...

DARE : 1.72 (+3.61%)
Dare Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will give one of the feature presentations at the 15 US-Japan Symposium on Drug Delivery Systems taking...

DARE : 1.72 (+3.61%)
Dare Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc. As...

DARE : 1.72 (+3.61%)
ANIK : 45.35 (-1.18%)
STIM : 4.35 (unch)
Dare Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company update.

DARE : 1.72 (+3.61%)
Dare Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene(R) Hormone-Free Contraceptive Candidate

-- Currently marketed contraceptives with similar results in their PCT clinical studies subsequently demonstrated 6-month "typical use" effectiveness of 86-91% in their pivotal clinical trials, in the...

DARE : 1.72 (+3.61%)
Dare Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it entered into an agreement to acquire privately-held Microchips Biotech, Inc. Dare entered into the agreement...

DARE : 1.72 (+3.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade DARE with:

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

2nd Resistance Point 1.79
1st Resistance Point 1.72
Last Price 1.72
1st Support Level 1.61
2nd Support Level 1.57

See More

52-Week High 3.25
Fibonacci 61.8% 2.27
Fibonacci 50% 1.97
Last Price 1.72
Fibonacci 38.2% 1.67
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar